T1D Exchange is helping Zucara Therapeutics recruit for their Phase 2 clinical trial evaluating an investigational drug that may help adults living with type 1 diabetes (T1D) who experience nighttime lows.
New study locations have recently been added across the U.S., making participation easier. If you live near one of the following locations, you may now be eligible for this clinical trial, even if you were previously disqualified. T1D Exchange is not a sponsor and is not administering this clinical trial, nor are we implying that you will qualify. We are sharing this research opportunity with you so you can decide whether to seek more information or participate.
Clinical Trial Details
Zucara Therapeutics, Inc., is conducting a clinical trial to evaluate an investigational medication that may lower the risk of experiencing low glucose levels during the night.
This clinical trial will help determine how well ZT-01, an investigational drug, works in reducing nighttime hypoglycemia and the safety and tolerability of three dose levels of ZT-01 in adults with T1D.
Eligibility Criteria
Zucara Therapeutics is looking for individuals who:
~Are between the ages of 18 to 75
~Have lived with T1D for at least five years
~Have recently experienced low glucose levels during the night.
*The guidelines listed above are the primary eligibility criteria for this study. Only the clinical trial research staff can determine if you meet all eligibility criteria for this study.
WHAT TO EXPECT IF YOU ENROLL IN THE CLINICAL TRIAL
Participation in the clinical trial will last approximately 16 weeks. During the trial, participants take subcutaneous injections with at least two weeks of no injections. The study requires six in-person visits and two phone calls over this period – approximately 16 weeks. The clinical trial research staff will communicate other requirements. Qualified participants will receive payment for time and travel
